COMBINATIONS OF MULTIPLE SERUM MARKERS ARE SUPERIOR TO INDIVIDUAL ASSAYS FOR DISCRIMINATING MALIGNANT FROM BENIGN PELVIC MASSES

被引:96
作者
WOOLAS, RP
CONAWAY, MR
XU, FJ
JACOBS, IJ
YU, YH
DALY, L
DAVIES, AP
OBRIANT, K
BERCHUCK, A
SOPER, JT
CLARKEPEARSON, DL
RODRIGUEZ, G
ORAM, DH
BAST, RC
机构
[1] DUKE UNIV, MED CTR, DUKE COMPREHENS CANC CTR, DEPT MED, DURHAM, NC 27110 USA
[2] DUKE UNIV, MED CTR, DUKE COMPREHENS CANC CTR, DEPT FAMILY & COMMUNITY MED, DURHAM, NC 27110 USA
[3] DUKE UNIV, MED CTR, DUKE COMPREHENS CANC CTR, DEPT OBSTET & GYNECOL, DURHAM, NC 27110 USA
[4] DUKE UNIV, MED CTR, DUKE COMPREHENS CANC CTR, DEPT IMMUNOL, DURHAM, NC 27110 USA
关键词
D O I
10.1006/gyno.1995.1276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine whether measurement of the levels of multiple tumor markers in the preoperative serum of women presenting with a pelvic mass distinguished benign from malignant disease better than the assay of CA 125 alone, sera from 429 patients, 192 of whom had malignant histology, were assayed for 8 different markers: CA 125, macrophage colony-stimulating factor, OVX1, lipid-associated sialic acid (LASA), CA15-3, CA72-4, CA19-9, and CA54/61. The sensitivity and specificity of CA 125 alone (> 35 U/ml) was 78.1 and 76.8%, respectively. A panel consisting of CA 125, OVX1, LASA, CA15-3, and CA72-4 had a sensitivity of 83.3% and specificity of 84.0% when two or more markers were elevated. Using the concentrations of these five markers, logistic regression analysis had a sensitivity of 85.4% and a specificity of 83.1%. Considering the values of markers in different sequences, classification and regression tree analysis substantially improved the sensitivity to 90.6% and the specificity to 93.2%. When applied in clinical practice this approach could improve the management of women presenting with a pelvic mass and may also have application in screening for ovarian cancer. (C) 1995 Academic Press, Inc.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 26 条
[1]  
[Anonymous], 2017, STAT MODELS S, DOI DOI 10.1201/9780203738535-9
[2]  
BAST RC, 1991, CANCER-AM CANCER SOC, V68, P1758, DOI 10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO
[3]  
2-#
[4]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[5]  
Brieman L., 1984, CLASSIFICATION REGRE
[6]  
EFRON B, 1982, P CBMS NSF REGIONAL
[7]  
EINHORN N, 1986, OBSTET GYNECOL, V67, P414
[8]  
FINKLER NJ, 1988, OBSTET GYNECOL, V72, P659
[9]  
FOX H, 1987, HAINES TAYLOR OBSTET, P714
[10]   THE CONCOMITANT DETERMINATION OF DIFFERENT TUMOR-MARKERS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER AND BENIGN OVARIAN MASSES - RELEVANCE FOR DIFFERENTIAL-DIAGNOSIS [J].
GADDUCCI, A ;
FERDEGHINI, M ;
PRONTERA, C ;
MORETTI, L ;
MARIANI, G ;
BIANCHI, R ;
FIORETTI, P .
GYNECOLOGIC ONCOLOGY, 1992, 44 (02) :147-154